Video
Author(s):
Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti—PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.
This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.